Early Treatment Evidence in Smoldering Multiple Myeloma

In this segment, Dr. Sagar Lonial asks the panel to reflect on how the treatment landscape has evolved for smoldering multiple myeloma and why early therapeutic intervention is increasingly being discussed for selected high-risk patients. Dr. Vincent Rajkumar explains that observation has historically been the standard approach because many patients with smoldering multiple myeloma may remain stable for extended periods without progression. However, emerging clinical trial data have begun to challenge this paradigm. He discusses studies evaluating lenalidomide-based strategies that demonstrated a delay in progression to active multiple myeloma among high-risk patients. Dr. Rajkumar notes that these findings provided some of the earliest evidence supporting early treatment in carefully selected individuals. At the same time, he emphasizes that clinicians must consider potential toxicities, long-term treatment exposure, and appropriate patient selection. The panel highlights that these early trials helped shape ongoing discussions about when early intervention may be appropriate in smoldering multiple myeloma.